IP Library Granted Patent US 8,722,064
Granted Patent B2
US 8,722,064 · App. 12/794,336 · Granted May 13, 2014

Synthetic glucopyranosyl lipid adjuvants

Inventors: Steven G. Reed (Bellevue, WA); Darrick Carter (Seattle, WA)
Assignee: Infectious Disease Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,722,064
App. No.
12/794,336
Granted
May 13, 2014
Kind
B2
Abstract

Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , L 10 , Y 1 , Y 2 , Y 3 , Y 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.

Claims (40)

1. A GLA compound having the following structure (IV):

or a pharmaceutically acceptable salt thereof, wherein:

L 1 , L 2 , L 3 , and L 4 are the same or different and independently —O—, —NH— or —(CH 2 )—;

Y 1 is an acid functional group;

Y 2 and Y 3 are the same or different and independently —OH, —SH, or an acid functional group; and

Y 4 is —OH or —SH.

2. A GLA compound according to claim 1 , wherein Y 1 is —OP(═O)(OH) 2 and Y 2 , Y 3 and Y 4 are each —OH.

3. A GLA compound according to claim 1 , wherein L 1 and L 3 are both —O— and L 2 and L 4 are both —NH.

4. A GLA compound according to claim 1 , wherein Y 1 is —OP(O)(OH) 2 , Y 2 , Y 3 and Y 4 are each —OH, L 1 and L 3 are both —O—, and L 2 and L 4 are both —NH.

5. A GLA compound having the following structure (IX):

or a pharmaceutically acceptable salt thereof.

6. A vaccine composition comprising a compound in combination with an antigen or a recombinant expression vector encoding an antigen, wherein the compound has the following structure (IV):

or a pharmaceutically acceptable salt thereof, wherein:

L 1 , L 2 , L 3 , and L 4 are the same or different and independently —O—, —NH— or —(CH 2 )—;

Y 1 is an acid functional group;

Y 2 and Y 3 are the same or different and independently —OH, —SH, or an acid functional group; and

Y 4 is —OH or —SH.

7. The vaccine composition of claim 6 wherein the recombinant expression construct is viral vector.

8. The vaccine composition of claim 7 wherein the viral vector is selected from the group consisting of an adenovirus vector, an adeno-associated virus vector, a herpesvirus vector, a lentivirus vector, a poxvirus vector and a retrovirus vector.

9. A method of eliciting or enhancing an antigen-specific immune response in a subject, the method comprising administering to the subject a vaccine composition of claim 6 .

10. A pharmaceutical composition comprising a compound and pharmaceutically acceptable carrier or excipient, wherein the compound has the following structure (IV):

or a pharmaceutically acceptable salt thereof, wherein:

L 1 , L 2 , L 3 , and L 4 are the same or different and independently —O—, —NH— or —(CH 2 )—;

Y 1 is an acid functional group;

Y 2 and Y 3 are the same or different and independently —OH, —SH, or an acid functional group; and

Y 4 is —OH or —SH.

11. A method for stimulating a non-specific immune response in a subject comprising administering to the subject a pharmaceutical composition of claim 10 .

12. The vaccine composition of claim 6 , wherein Y 1 is —OP(═O)(OH) 2 and Y 2 , Y 3 and Y 4 are each —OH.

13. The vaccine composition of claim 6 , wherein L 1 and L 3 are both —O— and L 2 and L 4 are both —NH—.

14. The vaccine composition of claim 6 , wherein the compound has the following structure (IX):

or a pharmaceutically acceptable salt thereof.

15. The pharmaceutical composition of claim 10 , wherein Y 1 is —OP(═O)(OH) 2 and Y 2 , Y 3 and Y 4 are each —OH.

16. The pharmaceutical composition of claim 10 , wherein L 1 and L 3 are both —O— and L 2 and L 4 are both —NH—.

17. The pharmaceutical composition of claim 10 , wherein the compound has the following structure (IX):

or a pharmaceutically acceptable salt thereof.

18. The vaccine composition of claim 6 wherein the antigen comprises a polypeptide antigen.

19. The method of claim 9 , wherein the compound in the vaccine composition is a compound having the following structure (IX):

or a pharmaceutically acceptable salt thereof.

20. The method of claim 11 , wherein the compound in the pharmaceutical composition is a compound having the following structure (IX):

or a pharmaceutically acceptable salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Oct 28, 2022
From: INFECTIOUS DISEASE RESEARCH INSTITUTE
To: ACCESS TO ADVANCED HEALTH INSTITUTE
Reel/Frame 063315/0207 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2010
From: REED, STEVEN G.; CARTER, DARRICK
To: INFECTIOUS DISEASE RESEARCH INSTITUTE
Reel/Frame 024842/0328 →
Continuity (2)
Provisional Application 61184703 · Jun 5, 2009
Related Publication 20100310602A1 · Dec 9, 2010